Prazosin Versus Quetiapine for Nighttime Posttraumatic Stress Disorder Symptoms in Veterans: An Assessment of Long-Term Comparative Effectiveness and Safety
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Posttraumatic stress disorder (PTSD) is an anxiety disorder experienced by combat veterans. Nighttime symptoms are often unrelieved by selective serotonin reuptake inhibitor therapy, and increased use of prazosin or quetiapine for treatment is seen. The purpose of this study was to determine the short- and long-term effectiveness and safety of prazosin versus quetiapine for treating nighttime symptoms in veteran PTSD patients. This is a historical prospective cohort study using retrospective chart review. Three hundred twenty-four patients with a diagnosis of PTSD, based on International Classification of Diseases, Ninth Revision coding, who were initially prescribed prazosin or quetiapine for nighttime symptoms were screened for inclusion. Short-term effectiveness was determined by documentation of symptomatic improvement within 6 months, and long-term effectiveness if patients continued therapy to study end date. Safety was assessed by comparing incidence of adverse drug effects causing discontinuation of either study drug. This study included 237 patients: 62 received prazosin, and 175 received quetiapine. Short-term effectiveness was similar for prazosin (61.3%) and quetiapine (61.7%; P = 0.54). However, patients prescribed prazosin were significantly more likely to continue their therapy to study end date compared with quetiapine (48.4% vs 24%; P < 0.001; odds ratio, 3.0; 95% confidence interval, 1.62-5.45), thus achieving long-term effectiveness. Alternatively, patients in the quetiapine group were more likely to discontinue therapy because of adverse effects compared with the prazosin group (34.9% vs 17.7%; P = 0.008). Because of similar rate of short-term effectiveness, superior long-term effectiveness, and lower incidence of events leading to discontinuation, compared with quetiapine, prazosin should be used first-line for treating nighttime PTSD symptoms in a veteran population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature?
Spoormaker, V. I., & Montgomery, P. (2008) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2007.08.008 · Cited by 527
CSF Norepinephrine Concentrations in Posttraumatic Stress Disorder
Geracioti, T. D., Baker, D. G., Ekhator, N. N., West, S. A., Hill, K. K., Bruce, A. B., Schmidt, D., Rounds-Kugler, B., Yehuda, R., Keck, P. E., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1227 · Cited by 462
REM sleep and the early development of posttraumatic stress disorder
Mellman, T. A., Bustamante, V., Fins, A. I., Pigeon, W. R., & Nolan, B. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1696 · Cited by 414 · cited 1×
“The drug’s proposed mechanism of action for this indication is counteracting noradrenergic stimulation, thus reducing the startle response and primitive fear response and normalizing sleep.(3,4) Similarly hypothesized, elevated levels of dopamine in PTSD patients may be affected by atypical antipsychotics, such as que…”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Atypical antipsychotics: Some data suggest that the atypical antipsychotics, risperidone (Level 2) [1030], aripiprazole (Level 3) [1031,1032], and quetiapine (Level 3) [1034,1035] may be a useful alternative to SSRIs for some patients with PTSD.”
BackgroundNoradrenergic modulation of wakefulness/arousal
Berridge, C. W., Schmeichel, B. E., & España, R. A. (2012) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2011.12.003 · Cited by 346
Treatment of Nightmares With Prazosin: A Systematic Review
Kung, S., Espinel, Z., & Lapid, M. I. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.05.015 · Cited by 277
Sleep Neurobiology from a Clinical Perspective
(2011) · Sleep · doi:10.5665/sleep.1112 · Cited by 277
Krystal, J. H., Davis, L. L., Neylan, T. C., A. Raskind, M., Schnurr, P. P., Stein, M. B., Vessicchio, J., Shiner, B., Gleason, T. D., & Huang, G. D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.007 · Cited by 265
“Additionally, prazosin has been found to be particularly helpful for insomnia and nightmares associated with PTSD (51-53) and showed significant efficacy in patients with greater than average baseline standing systolic blood pressure, a potential sign of noradrenergic activation, but its efficacy”
BackgroundLongitudinal Outcomes for Victims of Child Abuse
Buckingham, E. T., & Daniolos, P. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-012-0342-3 · Cited by 108
Sleep disturbances and PTSD: a perpetual circle?
van Liempt, S. (2012) · European Journal of Psychotraumatology · doi:10.3402/ejpt.v3i0.19142 · Cited by 93
Bajor, L. A., Ticlea, A. N., & Osser, D. N. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.614483 · Cited by 76
Bajor, L. A., Balsara, C., & Osser, D. N. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114840 · Cited by 43
Metadata
- Authors
- Byers, M. G., Allison, K. M., Wendel, C. S., & Lee, J. K.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2010-06
- Volume
- 30
- Issue
- 3
- Pages
- 225-229
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1980383761
- Cited by
- 88
- References
- 3
- FWCI
- 13.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.